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AbstrACt
Introduction Antimicrobial resistance (AMR) is a growing 
problem globally especially in Sub- Saharan Africa including 
Kenya. Without any intervention, lower/middle- income 
countries (LMICs) will be most affected due to already 
higher AMR levels compared with higher income countries 
and due to the far higher burden of diseases in the LMICs. 
Studies have consistently shown that inappropriate use 
of antimicrobials is the major driver of AMR. To address 
this challenge, hospitals are now implementing antibiotic 
stewardship programmes (ASPs), which have been shown 
to achieve reduced antibiotic usage, to decrease the 
prevalence of resistance and lead to significant economic 
benefits. However, the implementation of the guideline is 
highly dependent on the settings in which they are rolled 
out. This study, employing an implementation science 
approach, aims to address the knowledge gap in this area 
and provide critical data as well as practical experiences 
when using antibiotic guidelines and stewardship 
programmes in the public health sector. This will provide 
evidence of ASP performance and potentially contribute 
to the county, national and regional policies on antibiotics 
use.
Methods and analysis The study will be conducted in 
three geographically diverse regions, each represented 
by two hospitals. A baseline study on antibiotic usage, 
resistance and de- escalation, duration of hospital stay, 
rates of readmission and costs will be carried out in the 
preimplementation phase. The intervention, that is, the 
use of antibiotic guidelines and ASPs will be instituted for 
18 months using a stepwise implementation strategy that 
will facilitate learning and continuous improvement of 
stewardship activities and updating of guidelines to reflect 
the evolving antibiotic needs.
Ethics and dissemination Approvals to carry out the 
study have been obtained from the National Commission 
for Science, Technology and Innovation and the Mount 
Kenya University Ethics Review Committee. The approvals 
from the two institutions were used to obtain permission 
to conduct the study at each of the participating hospitals. 
Study findings will be presented to policy stakeholders 
and published in peer- reviewed scientific journals. It is 
anticipated that the findings will inform the appropriate 
antibiotic use guidelines within our local context.
IntroduCtIon
Antibiotic resistance is a serious public health 
concern globally1 2 and locally3 4 and fears of 
running out of antibiotic options in the near 
future have been expressed. In 2016, WHO 
called for immediate and concerted efforts 
to mitigate this threat to global health, which 
was estimated to contribute to 700 000 deaths 
in 2014 and projected to cause 10 million 
deaths in 2050, if inadequately mitigated.5 
The driving force escalating rates of resis-
tance is the injudicious use of antibiotics in 
patients, in livestock and in agriculture, and 
its unchecked release into the environment.6 
These forces raise and increase the spread 
of resistant pathogens that may emerge by 
mutations or acquisition of plasmids carrying 
resistance genes.7 In one study, prior antibi-
otic exposure was the key independent risk 
factor for the acquisition of antibiotic multi-
resistance.8 Broad- spectrum antibiotics have 
the unintended consequence of selecting 
multidrug- resistant pathogens and increasing 
the likelihood of infection by fungi and Clos-
tridium difficile.9
The injudicious use of antibiotics is wide-
spread. In Africa, many patients do not receive 
treatment from the conventional healthcare 
strengths and limitations of this study
 ► First study aimed at concurrently rolling out antimi-
crobial stewardship committees in multiple hospi-
tals in Kenya.
 ► Use of implementation approach to support imple-
mentation of suggested guidelines for antimicrobial 
resistance surveillance.
 ► First- hand evidence on the antimicrobial resistance 
in three diverse counties in Kenya.
 ► The study is limited to only 3 of the 47 counties in 
Kenya.
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system. Of those who receive antibiotics, 31.7% do not 
consult a doctor for a prescription and a further 26.4% 
obtain the antibiotics over the counter.10 A study in South 
Africa found that 54.9% of antibiotics were inappropri-
ately prescribed in intensive care unit settings while in the 
USA, 20%–50% of prescribed antibiotics were unneces-
sary or unwarranted.11–13
The rate of antimicrobial resistance in developing coun-
tries like Kenya is worrying and rising.14 For example, the 
prevalence of Salmonella typhi resistant to two or more 
antimicrobials was found to have increased from 50% in 
1998 to 78% in 2004 at Kenyatta National Hospital.15 The 
Global Antibiotic Resistance Partnership (GARP)—Kenya 
Working Group Report of 2011 identified antibiotic resis-
tance as a key issue in Kenya and made recommendations 
to curtail the spread.16 These recommendations included 
the use of antibiotic guidelines that took into consider-
ation local resistance surveillance data and enhanced 
antibiotic stewardship programmes (ASPs).16 However, 
these ASPs have not been instituted at county hospitals, 
and key implementation data and experiences are lacking 
in their roll out.
Antibiotic stewardship is defined as ‘the optimum selec-
tion, dosage, and duration of antimicrobial treatment 
that yields the best clinical outcomes for the treatment 
or prevention of infection with the least toxicity to the 
patient and minimal impact on subsequent resistance’.17 
It has the potential to lower treatment cost and realise 
economic benefits to the patient, healthcare system and 
the country at large.18 19 Moreover, optimising antibiotic 
use by minimising exposure, fine- tuning dosage and 
reducing superfluous therapy and focusing treatment 
to the likely culprit pathogens is a strategy that boosts 
patient safety20 and ultimately safeguards against antibi-
otic resistance.21
JustIfICAtIon
Antibiotic resistance is a major health challenge globally. 
Studies in Kenya have shown rising antibiotic resistance 
over the last three decades. While antibiotic guidelines 
and ASPs have been observed to lead to significant 
economic benefits, reduce antibiotic usage and lower 
the prevalence of resistance especially in Europe, North 
America, Japan and South Africa, they have not been 
employed to tackle the challenge in the public health 
sector in Kenya. The GARP report of 2011 recognised 
the use of guidelines and stewardship programmes as a 
potential strategy in ‘saving antibiotics’ but noted the 
need for local studies to understand implementation 
challenges, derive lessons and embed the strategy within 
the Kenyan healthcare system. The here proposed study, 
employing an implementation science approach, aims to 
address the knowledge and research gap in this area and 
provide critical data and experiences in using antibiotic 
guidelines and stewardship programmes in the public 
health sector.
obJECtIvEs of thE study
General objectives
The overall aim is to evaluate the impact of antibiotic 
guidelines for empirical treatment of (1) urinary tract 
infections, (2) community- acquired pneumonia, (3) 
bacteraemia and (4) meningitis in terms of reducing 
usage of broad- spectrum antibiotics, antibiotic de- escala-
tion, duration of hospital stays, rates of readmission and 
prevalence of antibiotic resistance in six county hospitals 
in Kenya.
specific objectives
1. To develop guidelines for antibiotic use for common 
infections.
2. To set up antibiotic steward committees (ASCs) in six 
county hospitals.
3. To train the ASC members such that they can fully per-
form their mandate.
4. To measure the usage of broad- spectrum antibiotics, 
antibiotic de- escalation, duration of hospital stays and 
rates of readmission in hospitals using the antibiotic 
stewardship strategy.
5. To ascertain antibiotic resistance patterns using cul-
ture, sensitivity and genetic markers.
6. To establish the knowledge of healthcare workers, 
their attitudes and prescription practices regarding an-
tibiotics resistance, use of guidelines and ASPs.
7. To evaluate the economic benefits of using guidelines 
for antibiotics use and ASPs.
Expected outputs of the research
1. Antibiotic guidelines informed by local bacteria sus-
ceptibility patterns.
2. ASCs in six county hospitals in Kenya.
3. Trained ASC members.
4. Data on antibiotics usage, antibiotic de- escalation, du-
ration of hospital stay and rates of readmission in hos-
pitals using the antibiotic stewardship strategy.
5. Map and data of antibiotic resistance patterns before 
and after implementation of the strategy.
6. Qualitative data on the knowledge of healthcare work-
ers, their attitudes and practices regarding antibiotic 
usage and stewardship programmes.
7. Publication on cost–benefit analysis (CBA) for using 
antibiotic guidelines and ASPs.
MEthods And AnAlysIs
setting
To be able to evaluate the antibiotic stewardship 
strategy across Kenya using an implementation science 
approach, the study will be conducted in six county 
hospitals, namely (1) Kiambu County Referral Hospital, 
(2) Bungoma County Hospital, (3) Webuye Sub- County 
Hospital, (4) Nakuru County Teaching and Referral 
Hospital, (5) Thika Level 5 Hospital and (6) Naivasha 
Sub- County Hospital.
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design
The study will use the Reach, Effectiveness, Adoption, 
Implementation and Maintenance (RE- AIM) conceptual 
framework. RE- AIM involves the interaction of all the five 
factors and fits well with approaches that are system based.22 
The study design will encompass a preimplementation 
phase, a stepwise implementation phase and an endline 
study to measure the changes in outcomes between the 
phases. A baseline study on antibiotic usage (defined daily 
doses (DDD) per 1000), antibiotic resistance (culture and 
genetic markers), antibiotic de- escalation, duration of 
hospital stays, rates of readmission, prescription patterns 
and cost analysis will be carried out in the preimplemen-
tation phase. The intervention, which is the use of antibi-
otic guidelines and ASPs, will be instituted in the 6 county 
hospitals for 18 months. The stepwise implementation 
phase will involve introduction of interventions as well 
as monitoring and evaluation of their effectiveness, and 
thereafter improving the interventions where necessary. 
The strategy will facilitate learning cycles every 4–6 weeks 
and continuous improvement of stewardship activities and 
updating of guidelines to reflect evolving antibiotic needs 
in diverse settings. During the intervention phase, chal-
lenges faced during the implementation of the guidelines 
will be documented and used to advise on the changes 
required during the review of the guidelines. The endline 
study will be conducted and differences between the two 
phases evaluated as per statistical analysis.
In the baseline and endline studies, multidisciplinary 
strategies will be employed as follows
1. Knowledge of healthcare workers, attitudes and prac-
tices on antibiotic resistance, guidelines and ASP will 
be studied qualitatively and quantitatively.
2. Basic science approaches, encompassing antibiotics 
culture sensitivity and molecular biology- genetic mark-
ers of resistance, will be analysed.
3. Clinical patient outcomes will be studied to evaluate 
the guidelines.
4. Health economics cost savings on using guidelines and 
ASP will be evaluated.
Antibiotic guidelines and AsPs: development
Antibiotic guidelines will be formulated in consultation 
with senior clinicians in the study hospitals taking into 
account each hospital’s antimicrobial resistance patterns. 
The ASP committee will comprise a hospital physician, 
a microbiologist and a pharmacist. Broad- spectrum anti-
biotic prescriptions will be brought to the attention of 
the ASP committee members. The committee members 
will perform regular ward rounds, three times a week, 
in the initial stages. This will be reduced to once a week 
later in the project, to optimise adherence to antibiotic 
guidelines. Furthermore, the guidelines will be promoted 
through training sessions, provision of pocket- size guide-
line cards to clinicians and pharmacists, large poster 
displays in the wards and through hospital and project 
websites and social media.
data collection
Laboratory assessment tools will be used to determine 
the preparedness of the laboratories to perform antibi-
otic sensitivity tests (see online supplementary file 1). 
The tool will assess whether the laboratories have the 
equipment necessary to perform bacterial culture, identi-
fication and susceptibility testing, such as carbon dioxide 
incubators, safety cabinets and refrigerators. The tool will 
also determine whether the laboratories have the inter-
nationally recommended guidelines to perform suscepti-
bility and quality assurance tests. In addition, knowledge, 
attitude and practices (KAPs) about antibiotic prescrip-
tion and resistance among medical practitioners will be 
assessed using a KAP tool (see online supplementary file 
2). The tool will target those medical practitioners, who 
usually prescribe antimicrobial drugs in the hospitals and 
will include the consultants, medical officers as well as 
interns, clinical officers and pharmacists. The KAP tool 
will also determine the guidelines that the prescribers 
use to decide on the appropriate antimicrobial drug. A 
health system assessment tool will be employed to gather 
baseline information on the antimicrobial stewardship 
activities in each hospital (see online supplementary file 
3). Information on bed occupancy, antibiotic usage and 
antibiotic resistance data will be collected from each of 
the hospital information systems, pharmacy management 
systems and laboratory reporting systems, respectively. 
Antibiotic usage will be analysed in order to determine the 
impact of the intervention on antibiotic usage comparing 
the intervention and the control arms. Data on antibi-
otics issued to adult and children inpatients only will be 
factored, excluding discharge and outpatient supplies.
To consistently compare antibiotic usage, the DDD 
will be used and expressed per 1000 occupied bed days 
(OBDs) to account for fluctuations in activity following 
WHO guidelines.23 The OBDs will be obtained from the 
hospital information systems.
Culture sensitivity and genetic analyses
Nasal swabs or tracheal aspirate, urine, wound swabs 
and blood samples will be taken from patients who 
have consented to the study for bacteriological analysis. 
Samples will be subjected to standard bacteriological anal-
ysis to isolate the culprit bacteria. Bacterial species will 
be confirmed by use of biochemical test and analytical 
profiles index API strips (bioMérieux France). Antimi-
crobial susceptibility tests will be performed on isolated 
bacteria as per the Kirby- Bauer method following manu-
facturer’s instruction. Results will be interpreted using 
the Clinical and Laboratory Standards Institute tables.24
Any bacteria isolate found to be resistant to third 
generation cephalosporins will be tested for production 
of extended spectrum beta- lactamase (ESBL) using the 
synergy disk diffusion test. Vancomycin- resistant Entero-
cocci (VRE) will be identified using disc diffusion tests. 
Methicillin- resistant Staphylococcus aureus (MRSA) will be 
detected by testing isolates resistant to cefoxitin using the 
E test (AB Biodisk, Solna, Sweden) on Mueller- Hinton 
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Figure 1 Statistical power analysis for sample size 
determination for the prevalence of inappropriate use of 
broad- spectrum antibiotics.
Figure 2 Statistical power analysis for sample size 
determination for the prevalence of antibiotics resistance.
agar supplemented with 2% NaCl and incubated at 
37°C for 24 hours. The identified ESBL, VRE and MRSA 
samples will be analysed by PCR and sequencing to iden-
tify the resistance genotype. In vitro conjugation tests will 
be performed to determine if resistance in bacteria is 
transferable.
CbA for the use of antibiotic guidelines and AsP
A CBA from a health facility and a national perspec-
tive will be performed. For health facilities, three cost 
drivers will be considered: (1) pharmacy spending, (2) 
length of stay and (3) antimicrobial stewardship inter-
ventions (training, infection control measures and so 
on). At country level, we will consider disability- adjusted 
life years, work- days lost and cost of treatment.25–27 This 
will be done by collecting and analysing data on patient 
income, length of hospital stay, death or disability occa-
sioned by drug- resistant pathogens, hospital pharmacy 
expenditure and cost of training/rolling out antimicro-
bial stewardship guidelines. This data will be collected 
before and after antimicrobial stewardship interventions.
study size
Prevalence of inappropriate use of broad-spectrum antibiotics
The sample size is based on the prevalence of inappro-
priate use of broad- spectrum antibiotics, documented as 
being about 50% in South Africa.11 To detect a reduction 
of the 50% inappropriate use of broad- spectrum antibi-
otics by 20%–30% with a power of 90% and α of 0.05 in a 
two- sided test, a sample size of 410 in each county hospital 
would be adequate. In order to detect a reduction (20%) 
but with a power 80%, the sample size would be 320 
as shown in figure 1. With a 15% allowance for loss to 
follow- up, a total of about 500 participants would be suffi-
cient in each of the selected county hospitals. Therefore, 
we shall evaluate the prevalence of inappropriate use of 
broad- spectrum antibiotics in 500×6= 3000 patients from 
the six facilities.
Prevalence of antibiotic resistance
The sample size is based on the prevalence of antibiotic 
resistance of 78%15 in 2004 at Kenyatta National Hospital, 
Kenya. To detect a reduction of the 78% antibiotic resis-
tance by 10%–68% with a power of 90% and α of 0.05 
two- sided test, a sample size of 500 in each county hospital 
would be adequate; while to achieve a reduction of 10% 
with power 80%, the sample size would need to be 220 
(figure 2). With 15% allowance for loss to follow- up, a 
total of 600 participants would be sufficient in each of the 
selected county hospitals. Therefore, we shall evaluate 
the prevalence of resistance in 600×6 = 3600 patients for 
the 6 facilities.
data management
Data will be recorded on a standardised case report form 
at every hospital by the trained study staff. The data will 
be held locally and uploaded to the secure central study 
server hosted at the Mount Kenya University main campus 
in Thika. This will be overseen by the data manager/
statistician, who will run regular reconciliation to derive 
the final study database. Access to the study database 
will be restricted and password protected. The data will 
be stored in excel, jpeg and word files for the electronic 
cases. For archiving purposes, the Mount Kenya Univer-
sity electronic repository will be used to ensure that the 
data are publicly available. Collected data will be retained 
according to the policy governing the Mount Kenya 
University repository. The principal investigators involved 
in this study do not have any reasons that might prohibit 
the sharing of the data emanating from the study.
statistical analysis
The data will be analysed using qualitative and quan-
titative methods. Qualitative data will be analysed by 
subjecting the information to content analysis and 
presenting it in different emerging themes. The summa-
ries of the data emanating from these themes will then 
be arranged on a case- by- case basis through the use of 
an Excel spreadsheet28 and the analyses performed using 
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NVivo software. Quantitative data analyses will be carried 
out using Stata V.14 (Stata). The differences between 
baseline and endline on all the study outcomes will be 
compared using appropriate statistical methods, such as 
McNemar’s test, paired t- test and the Wilcoxon signed- 
rank test (non- parametric test), accounting for pairing 
and clusters (hospitals). Multivariable log- binomial 
regression analysis will be used to elucidate risk factors 
for antibiotic resistance.
EthICs And dIssEMInAtIon
Approvals to carry out the study have been obtained from 
the National Commission for Science, Technology and 
Innovation (NACOSTI) (NACOSTI/P/18/33304/25986) 
and the Mount Kenya University Ethics Review Committee 
(MKU/ERC/0764). In addition, permission was obtained 
from each of the participating hospitals. This entailed 
submission of an introduction letter attaching the certif-
icate of clearance from NACOSTI and the ethical review 
certificate from MKU. In Thika, Nakuru and Naivasha, a 
research fee was paid as required by the hospital board. 
The study will follow all provisions of the Declaration of 
Helsinki. Participants in the study will not incur any cost 
associated with the transport or processing of the samples; 
neither will they receive any monetary inducements to 
participate in the study. Material transfer to laboratories 
outside of Kenya shall not be undertaken in this study. 
Informed written consent will be sought from the partici-
pants enrolled in the study.
Obtained results will be disseminated via different 
streams, including research conferences and in peer- 
reviewed journals. We are aiming for five publications 
to be generated by the end of the study. These will 
include the study protocol itself and the different aspects 
emerging during in the course of the project. Contex-
tualised guidelines on judicious use of antibiotics in 
the six hospitals in Kenya will also be published in the 
Ministry of Health’s website and that of the collaborating 
hospitals for easy access by other health facility in and 
outside Kenya. In addition, the findings will be shared 
in a dissemination forum bring together members of 
the health management teams at both the country and 
county levels, clinicians who do prescription of antimicro-
bial drugs, researchers, members of the public and other 
key stakeholders. The dissemination forum will be held 
once at the end of the study.
Patient and public involvement
The study is mainly targeting clinicians who do antimi-
crobial proscription and, therefore, patients will not be 
directly involved in the study. Reports obtained from this 
study will, however, be made available to the patients 
in the participating hospitals through a dissemination 
forum and to the general public through publications.
Exit strategy and stakeholder involvement
In the process of developing this protocol, we have 
engaged physicians working in the proposed county 
hospitals, and they have identified the challenge of anti-
biotic resistance as real and appreciate the opportunities 
that use of antibiotic guidelines and ASPs may provide in 
combating resistance, improving clinical care and saving 
costs. We plan to continue involving all the stakeholders 
in the process, including clinicians, laboratory personnel, 
pharmacists, public health officials, patients and scientists. 
We anticipate that the study findings will inform county 
and national policy on mitigating antibiotic resistance 
and raise public awareness on the need for judicious use 
of antibiotics. The project will use social media platforms, 
websites of the collaborating institutions and publications 
in peer- reviewed journals, local dailies and presentations 
in scientific meetings to further engage stakeholders 
and the public on this important issue and enhance the 
learning approach inherent in the strategy of implemen-
tation science for improved performance of the ASPs and 
the study in general. In case any of the hospitals dropout 
either during the baseline phase or early stages of the 
implementation phase, another hospital will be brought 
onboard. Replacements will not be considered during the 
late stages of the project.
dIsCussIon
The emergence of antimicrobial- resistant pathogens and 
a lack of new drugs to effectively treat these pathogens are 
the two main challenges in human health. There is thus 
the need to advocate the proper use of the currently avail-
able antimicrobial agents by safeguarding their effective-
ness. Antibiotic stewardship has been shown to contribute 
to reducing antibiotic resistance,29 30 but this strategy has 
not been rolled out in most sub- Saharan countries in 
level 4 and 5 hospitals. The proposed work will employ 
an implementation research approach to evaluate the 
best strategies and derive lessons on mainstreaming anti-
biotic stewardship in these facilities. By leveraging on a 
health system approach, the implementation research 
will unravel real- life impediments and opportunities by 
working with hospital teams to codesign execution plans, 
monitor and evaluate and the sustainability of the stew-
ardship programmes.
Most hospitals in Kenya lack the capacity to carry out 
antimicrobial sensitivity tests, due to the lack of resources 
and technical knowhow, among other challenges.31 This 
study will first provide an assessment to determine the 
challenges hospitals are facing; this will be done through 
interviews with clinicians and assessment of the capacity 
of the laboratories to perform the sensitivity tests. These 
steps will make up the initial phase and will guide the 
nature of implementations to be used during the imple-
mentation phase. It is hoped that the project will capac-
itate the laboratories in the six hospitals to do the tests 
and sensitise the clinicians on the need to prescribe anti-
microbial drugs based on results obtained from the labo-
ratory tests. After the implementation phase, the endline 
phase will involve surveys similar to those conducted 
during the baseline phase. This will allow determination 
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Table 1 Proposed study timelines
Activity
2019 2020 2021
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Ethics clearance and authorisation from 
study sites
Baseline study on prevalence of antibiotic 
resistance and stewardship activities
Identification of members for the antibiotic 
stewardship programmes (ASPs)
Development of antibiotic guidelines
Adopting and preparing materials for ASP 
training
Development of antibiotic guidelines and 
stewardship mobile application
Training the ASP members
Collecting data on antibiotic usage in the 
hospitals
Conducting KAPs study on use of guidelines 
and ASPs
Analyse and present antibiotic resistance 
data using maps and charts
Presenting findings to stakeholders and 
preparing the final report
KAP, knowledge, attitude and practices.
of the impact of the implementation strategies taken in 
reducing the cost of treatment, length of hospital stay and 
burden on the health system, among others.
The hospital management teams play a key role in 
determining the allocation of resources to and within the 
hospitals.32 In this project, we have proposed to involve 
hospital management by including its members in the 
stewardship committees that will be established. This will 
ensure that the management is well informed about the 
challenges in the sections involved in surveillance and the 
progress that is being made. Involvement of the hospital 
management will also ensure that there is a buy- in of the 
recommendations made by the stewardship committee.
Although there is the need to establish antimicrobial 
stewardship committees in all the hospitals, the project 
proposes to start with the selected six hospitals with the 
hope that the same can be reproduced by other hospitals 
to establish similar committees in their hospitals.
study timeline
The study is designed for a 3- year period. Enrolment 
already started in 2018 and participant recruitment will 
continue up to 2020 (table 1). So far, stewardship commit-
tees have been established and workshops to sensitise the 
members conducted. Data collection on KAP of antibi-
otic prescribers in the hospitals is already in progress.
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